Form 4: Tonix Pharmaceuticals Director Receives Stock Options

Director Carolyn E. Taylor was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Summary

• Director Carolyn E. Taylor received a grant of 22,700 stock options on May 12, 2026.
• The options have an exercise price of $13.28 per share.
• The options vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
• The options expire on May 12, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $13.28 exercise price.

Future Outlook

The grant is part of the 2026 Stock Incentive Plan, indicating ongoing equity-based compensation strategies for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board retention and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a one-year vesting schedule is consistent with standard industry practices for non-employee director compensation.
• The grant size is typical for mid-cap and small-cap pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 12, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Form 4, Insider Trading, Stock Options, Director Compensation